RVMDHealthcareLarge-Cap
Revolution Medicines, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Revolution Medicines, Inc. (RVMD), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are RVMD insiders buying or selling?
Revolution Medicines, Inc. insiders reported 11 open-market buys ($134.5M) and 223 sells ($408.7M) across 234 Form 4 filings — a net selling position of $274.2M.
Source: SEC EDGAR Form 4
Key Statistics (as of Sep 2, 2026)
Total Form 4 filings
234
SEC EDGAR
Insider filers
19
Insider buys (11)
$134.5M
Insider sells (223)
$408.7M
Insider sentiment
Net sellingNet insider flow of $274.2M in net selling.
Recent RVMD insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Lorence H. Kim | Director | Sale | 56.0K | $203.24 | $11.4M |
| Aug 25, 2026 | Jeff Cislini | General Counsel | Sale | 56.9K | $209.24 | $11.9M |
| Aug 25, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 86.0K | $209.20 | $18.0M |
| Jul 1, 2026 | Sushil Patel | Director | Sale | 5.6K | $187.99 | $1.0M |
| Jun 26, 2026 | Jack Anders | Chief Financial Officer | Sale | 20.0K | $168.33 | $3.4M |
| Jun 18, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 4.6K | $156.12 | $720.5K |
| Jun 18, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 10.0K | $156.12 | $1.6M |
| Jun 18, 2026 | Jeff Cislini | General Counsel | Sale | 2.2K | $156.12 | $336.7K |
| Jun 18, 2026 | Jack Anders | Chief Financial Officer | Sale | 2.7K | $156.12 | $425.0K |
| Jun 18, 2026 | Stephen Michael Kelsey | President, Research and Development | Sale | 4.2K | $156.12 | $651.8K |
| Jun 17, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 93.6K | $160.00 | $15.0M |
| Jun 15, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 10.0K | $148.01 | $1.5M |
| May 28, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 3.1K | $153.99 | $480.6K |
| Apr 29, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 3.1K | $132.41 | $413.1K |
| Apr 17, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 120.0K | $150.09 | $18.0M |
| Mar 27, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 37.5K | $95.56 | $3.6M |
| Mar 19, 2026 | Lin Wei | Chief Medical Officer | Sale | 2.1K | $99.48 | $206.2K |
| Mar 19, 2026 | Stephen Michael Kelsey | President, Research and Development | Sale | 4.3K | $99.48 | $428.0K |
| Mar 19, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 12.9K | $99.48 | $1.3M |
| Mar 19, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 4.6K | $99.48 | $455.9K |
| Mar 19, 2026 | Jack Anders | Chief Financial Officer | Sale | 2.8K | $99.48 | $273.9K |
| Mar 19, 2026 | Jeff Cislini | General Counsel | Sale | 3.0K | $98.68 | $291.9K |
| Mar 19, 2026 | Xiaolin Wang | EVP, Clinical Development | Sale | 2.0K | $99.48 | $200.0K |
| Mar 4, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 36.0K | $101.23 | $3.6M |
| Jan 23, 2026 | Jeff Cislini | General Counsel | Sale | 908 | $115.60 | $105.0K |
Showing the 25 most recent of 234 Form 4 filings for Revolution Medicines, Inc..
Most active RVMD insiders
- Mark A Goldsmith43 filings
- Stephen Michael Kelsey41 filings
- Margaret A Horn34 filings
- Jeff Cislini32 filings
- Jack Anders30 filings
Ask anything about RVMD insider activity
Use Trabud's AI agent to query Revolution Medicines, Inc.'s Form 4 history in plain English — "Show me RVMD CEO purchases this year" or compare it against any other ticker.
Open the AI agentRVMD insider trading FAQ
Are Revolution Medicines, Inc. insiders buying or selling?
Across 234 SEC Form 4 filings, Revolution Medicines, Inc. (RVMD) insiders reported 11 open-market purchases totaling $134.5M and 223 sales totaling $408.7M. That is a net selling position of $274.2M.
How many insiders trade RVMD stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Revolution Medicines, Inc.. The most recent filing was accepted on Sep 2, 2026.
Where does Trabud get RVMD insider trading data?
All RVMD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.